See the published version of this preprint at BMC Infectious Diseases.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Miriam Reuschenbach
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4268-6250
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Most women and men are infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data.
Methods
We conducted a retrospective claims data analysis using the “Institute for Applied Health Research Berlin” (InGef) research database, containing claims data from approximately 4 million insured individuals. In the period from 2012-2017 all women born in1989-1992, who were continuously insured between the age of 23-25 years were identified. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.8, N87.0, N89.0, N90.0), grade II (N87.1, N89.1, N90.1) and grade III (D01.3, D06.-, D06.0, D07.1, D07.2, N87.2, N89.2, N90.2) was calculated (women with diagnosis divided by all women).
Results
From 2012-2017, a total of 15,358 (birth cohort 1989), 16,027 (birth cohort 1990), 14,748 (birth cohort 1991) and 14,862 (birth cohort 1992) women at the age of 23-25 were identified. A decrease of the administrative prevalence was observed in genital warts (1.30% (1.12-1.49) birth cohort 1989 vs. 0.94% (0.79-1.10) birth cohort 1992) and anogenital diseases grade III (1.09% (0.93-1.26) birth cohort 1989 vs. 0.71% (0.58-0.86) birth cohort 1992). In anogenital diseases grade III, this trend was especially observed for severe cervical dysplasia (N87.2) (0.91% (0.76-1.07) birth cohort 1989 vs. 0.60% (0.48-0.74) birth cohort 1992). In contrast, anogenital diseases grade I (1.41% (1.23-1.61) birth cohort 1989 vs. 1.31% (1.14-1.51) birth cohort 1992) and grade II (0.61% (0.49-0.75) birth cohort 1989 vs. 0.52% (0.42-0.65) birth cohort 1992) remained stable.
Conclusions
A decrease of the burden of anogenital disease potentially related to HPV was observed in the younger birth cohorts. This was observed especially for genital warts and anogenital diseases grade III. Further research to investigate this trend for the upcoming years in light of varying HPV vaccination coverage for newer birth cohorts is necessary.
Keywords
Human papillomavirus (HPV), Genital warts, Cervical intraepithelial neoplasia, Prevalence, Claims data, Statutory health insurance, Germany
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Infectious Diseases.
No community comments so far
Editor assigned
On 22 Mar, 2020
Editor invited
On 21 Mar, 2020
Submission checks complete
On 18 Mar, 2020
Editorial decision: Minor revision
On 18 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 13 Mar, 2020
Editor assigned
On 03 Mar, 2020
Submission checks complete
On 02 Mar, 2020
Editor invited
On 02 Mar, 2020
Version 2
Posted 10 Dec, 2019
No comments provided
Review #2 received
Received 17 Feb, 2020
Editorial decision: Minor revision
On 17 Feb, 2020
Reviewer #2 agreed
On 02 Feb, 2020
Review #1 received
Received 16 Jan, 2020
Reviewer #1 agreed
On 31 Dec, 2019
Reviewers invited
Invitations sent on 28 Dec, 2019
Editor assigned
On 04 Dec, 2019
Submission checks complete
On 03 Dec, 2019
Editor invited
On 03 Dec, 2019
No comments provided
Review #2 received
Received 02 Nov, 2019
Editorial decision: Major revision
On 02 Nov, 2019
Reviewer #2 agreed
On 01 Oct, 2019
Review #1 received
Received 28 Aug, 2019
Reviewer #1 agreed
On 18 Aug, 2019
Editor assigned
On 15 Aug, 2019
Reviewers invited
Invitations sent on 15 Aug, 2019
Submission checks complete
On 07 Aug, 2019
Editor invited
On 07 Aug, 2019
First submitted
On 30 Jul, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Health Economics & Outcomes Research
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Infectious Diseases.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Miriam Reuschenbach
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4268-6250
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Infectious Diseases.
No community comments so far
Editor assigned
On 22 Mar, 2020
Editor invited
On 21 Mar, 2020
Submission checks complete
On 18 Mar, 2020
Editorial decision: Minor revision
On 18 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 13 Mar, 2020
Editor assigned
On 03 Mar, 2020
Submission checks complete
On 02 Mar, 2020
Editor invited
On 02 Mar, 2020
Version 2
Posted 10 Dec, 2019
No comments provided
Review #2 received
Received 17 Feb, 2020
Editorial decision: Minor revision
On 17 Feb, 2020
Reviewer #2 agreed
On 02 Feb, 2020
Review #1 received
Received 16 Jan, 2020
Reviewer #1 agreed
On 31 Dec, 2019
Reviewers invited
Invitations sent on 28 Dec, 2019
Editor assigned
On 04 Dec, 2019
Submission checks complete
On 03 Dec, 2019
Editor invited
On 03 Dec, 2019
No comments provided
Review #2 received
Received 02 Nov, 2019
Editorial decision: Major revision
On 02 Nov, 2019
Reviewer #2 agreed
On 01 Oct, 2019
Review #1 received
Received 28 Aug, 2019
Reviewer #1 agreed
On 18 Aug, 2019
Editor assigned
On 15 Aug, 2019
Reviewers invited
Invitations sent on 15 Aug, 2019
Submission checks complete
On 07 Aug, 2019
Editor invited
On 07 Aug, 2019
First submitted
On 30 Jul, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Health Economics & Outcomes Research
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Infectious Diseases.
Background
Most women and men are infected with human papillomavirus (HPV) at least once in their lifetime. Infections with low-risk types can cause genital warts, whereas high-risk types can cause malignant tumors. The aim of this study was to determine the burden of anogenital diseases potentially related to HPV in young women based on German statutory health insurance claims data.
Methods
We conducted a retrospective claims data analysis using the “Institute for Applied Health Research Berlin” (InGef) research database, containing claims data from approximately 4 million insured individuals. In the period from 2012-2017 all women born in1989-1992, who were continuously insured between the age of 23-25 years were identified. Using ICD-10-GM codes (verified diagnosis in the outpatient sector or primary or secondary diagnosis in the inpatient sector) the administrative prevalence (95% confidence interval) of genital warts (A63.0), anogenital diseases grade I (K62.8, N87.0, N89.0, N90.0), grade II (N87.1, N89.1, N90.1) and grade III (D01.3, D06.-, D06.0, D07.1, D07.2, N87.2, N89.2, N90.2) was calculated (women with diagnosis divided by all women).
Results
From 2012-2017, a total of 15,358 (birth cohort 1989), 16,027 (birth cohort 1990), 14,748 (birth cohort 1991) and 14,862 (birth cohort 1992) women at the age of 23-25 were identified. A decrease of the administrative prevalence was observed in genital warts (1.30% (1.12-1.49) birth cohort 1989 vs. 0.94% (0.79-1.10) birth cohort 1992) and anogenital diseases grade III (1.09% (0.93-1.26) birth cohort 1989 vs. 0.71% (0.58-0.86) birth cohort 1992). In anogenital diseases grade III, this trend was especially observed for severe cervical dysplasia (N87.2) (0.91% (0.76-1.07) birth cohort 1989 vs. 0.60% (0.48-0.74) birth cohort 1992). In contrast, anogenital diseases grade I (1.41% (1.23-1.61) birth cohort 1989 vs. 1.31% (1.14-1.51) birth cohort 1992) and grade II (0.61% (0.49-0.75) birth cohort 1989 vs. 0.52% (0.42-0.65) birth cohort 1992) remained stable.
Conclusions
A decrease of the burden of anogenital disease potentially related to HPV was observed in the younger birth cohorts. This was observed especially for genital warts and anogenital diseases grade III. Further research to investigate this trend for the upcoming years in light of varying HPV vaccination coverage for newer birth cohorts is necessary.
Figure 1
Loading...